This study is testing a new way to treat blood cancers like B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Plasma Cell Leukemia. It uses special immune cells called natural killer (NK) cells that have been engineered to target cancer. These CAR.70/IL15-transduced CB-NK cells are given through an IV, along with chemotherapy drugs called Cyclophosphamide and Fludarabine phosphate. Researchers want to see how safe this treatment is and how well it works. To join, your tumor must show a certain level of a marker called CD70. Success in this study means seeing if the treatment causes side effects, if your cancer shrinks or disappears, and if you remain alive and in remission after treatment.

Study design

This is an interventional study planning to enroll 80 participants. It is designed to evaluate the safety and effectiveness of the treatment.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will monitor participants for treatment-related side effects throughout the study (about 1 year), check for cancer response up to 30 days after the last treatment, and track if participants are alive and in remission for up to 180 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.